{"id":"W2965985902","doi":"10.1200/jco.2012.30.15_suppl.4019","title":"Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Gemcitabine; Internal medicine; Phases of clinical research; Epidermal growth factor receptor; Oncology; Clinical endpoint; Neutropenia; Progression-free survival; Gastroenterology; Cancer; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002508308,0.002322709,0.001956736,0.0006231539,0.0003700954,0.001068043,0.001282539,0.001396735,0.004273095],"category_scores_gemma":[0.0009277562,0.0009101094,0.001203558,0.0005409693,0.001316752,0.00118249,0.0004766101,0.004884196,0.0008927244],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001225958,"about_ca_system_score_gemma":0.002224618,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007054842,"about_ca_topic_score_gemma":0.002324308,"domain_scores_codex":[0.9994467,0.0002989769,0.0000272338,0.00009453116,0.00005275781,0.00007973695],"domain_scores_gemma":[0.999217,0.0001498527,0.0001709852,0.00004447605,0.00003872147,0.0003789882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8952674,0.04204252,0.002243131,0.0007072164,0.0008064508,0.0001080267,0.0001092409,0.001412504,0.02455956,0.0002231234,0.002103013,0.03041779],"study_design_scores_gemma":[0.7669319,0.2244643,0.002736437,0.00002708175,0.0003217335,0.0001355994,0.00002758635,0.0008498525,0.003335597,0.0001141372,0.001036045,0.00001975711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915401,0.001800971,0.0003825774,0.0005766245,0.0001748129,0.003257045,0.0007799222,0.00008999448,0.001397948],"genre_scores_gemma":[0.9880579,0.0015228,0.001810824,0.0008204776,0.0002465539,0.003792237,0.001373739,0.00002864994,0.002346884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004273095,"threshold_uncertainty_score":0.01429492,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1487944595752655,"score_gpt":0.4710229762490449,"score_spread":0.3222285166737793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}